Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
(Thomson Reuters ONE) -
Novartis International AG /
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance
retinal surgeon experience
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Heads-up design using high definition 3D screen engineered to improve
surgeons posture and may reduce fatigue[1]
* Offers enhanced 3D visualization with high-definition resolution, image
depth, clarity and color contrast while helping to minimize light exposure
to the patient's eye
* Vitreoretinal surgeries may range from thirty minutes to over three hours in
length
The digital press release with multimedia content can be accessed here:
Basel, September 8, 2016 - Alcon, the global leader in eye care and a division
of Novartis, launches the NGENUITY(®) 3D Visualization System, a platform for
Digitally Assisted Vitreoretinal Surgery (DAVS). The system is designed to
enhance visualization of the back of the eye for improved surgeon experience.
Alcon is launching the system in collaboration with TrueVision(® )3D Surgical, a
California-based company specializing in digital 3D visualization and guidance
for microsurgery.
The NGENUITY(®) 3D Visualization System allows retinal surgeons to operate
looking at a high definition 3D screen, instead of bending their necks to look
through the eye-piece of a microscope. Traditional vitrectomy surgeries range
from 30 minutes to over three hours in length to complete. This microscope-free
design is engineered to improve surgeons' posture and may reduce fatigue.[1]
The NGENUITY 3D Visualization System is comprised of several elements, notably a
High Dynamic Range (HDR) camera that provides excellent resolution, image depth,
clarity and color contrast. With the three-dimensional view, the surgeon now has
depth perception not previously available on standard television monitors, often
used today in the operation theatre. Surgeons may also increase magnification
while maintaining a wide field of view as well as use digital filters to
customize his or her view during each procedure, highlighting ocular structures
and tissue layers which is imperative to visualize the back of the eye.
Engineered with a specific focus on minimizing light exposure to the patient's
eye, the NGENUITY 3D Visualization System facilitates operating using lower
light levels.[1]
"This digital platform offers more than just enhanced visualization. It will
impact our therapies and the way we manipulate tissue," said Dr. Allen Ho,
Professor of Ophthalmology, Thomas Jefferson University and Director of Retina
Research Wills Eye Hospital, Philadelphia, PA, USA. "The easier it is for
surgeons to perform these long, delicate surgeries, the better they can perform
for our patients who count on us to provide them with the best possible care."
The system is designed to facilitate collaboration and teaching in the operating
room. Offering an immersive panoramic surgical view, the NGENUITY 3D
Visualization System allows the operating team to see exactly what the surgeon
is seeing in real-time.
"The NGENUITY 3D Visualization System takes vitreoretinal surgery to a more
intuitive operating experience, offering greater depth and detail during
surgery," said Mike Ball, CEO of Alcon. "Our goal is to provide surgeons with
better visualization while operating on the back of the eye, facilitate teaching
and ultimately improve patient outcomes."
The NGENUITY(®) 3D Visualization System is expected to be available in the
United States and specific countries within Europe as of September 15, 2016, and
is expected to be available in Japan in December of this year. Other countries
are expected to launch the NGENUITY(®) 3D Visualization System over the course
of 2017.
About Vitreoretinal Surgery[2]
Vitreoretinal surgery is a sub-specialty of ophthalmology focused in diseases
and surgery of the back of the eye including the retina and the vitreous body of
the eye. The retina is a light-sensitive area that includes the macula, which is
made up of light-sensitive cells that provide sharp, detailed vision. The
vitreous body of the eye is a clear gel that fills the space between the retina
and the lens. The retina, the macula, and the vitreous body can all be subject
to various diseases and conditions that can lead to blindness or vision loss and
may require the attention of a vitreoretinal surgeon.
About NGENUITY
The NGENUITY(®) 3D Visualization System was developed in collaboration with
TrueVision(® )3D Surgical, a California-based leader in digital 3D visualization
and guidance for microsurgery. It consists of a 3D stereoscopic, high-definition
digital video camera and workstation to provide magnified stereoscopic images of
objects during micro-surgery. It acts as an adjunct to the surgical microscope
during surgery displaying real-time images or images from recordings. Please
refer to the User Manual for a complete list of appropriate uses, warnings and
precautions.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "launches," "designed to," "engineered to," "may," "offers,"
"launching," "will," "offering," "goal," "ultimately," "expected," "can," or
similar terms, or by express or implied discussions regarding potential
marketing approvals and launches of the NGENUITY 3D Visualization System, or
regarding potential future revenues from the NGENUITY 3D Visualization System.
You should not place undue reliance on these statements. Such forward-looking
statements are based on the current beliefs and expectations of management
regarding future events, and are subject to significant known and unknown risks
and uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that the NGENUITY 3D Visualization System will be
submitted or approved for sale in any market, or at any particular time. Neither
can there be any guarantee that the NGENUITY 3D Visualization System will be
launched in any market, or at any particular time. Nor can there be any
guarantee that the NGENUITY 3D Visualization System will be commercially
successful in the future. In particular, management's expectations regarding the
NGENUITY 3D Visualization System could be affected by, among other things, the
uncertainties inherent in research and development, including unexpected
clinical trial results and additional analysis of existing clinical data;
unexpected regulatory actions or delays or government regulation generally; the
company's ability to obtain or maintain proprietary intellectual property
protection; general economic and industry conditions; global trends toward
health care cost containment, including ongoing pricing pressures; unexpected
safety, quality or manufacturing issues, and other risks and factors referred to
in Novartis AG's current Form 20-F on file with the US Securities and Exchange
Commission. Novartis is providing the information in this press release as of
this date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2015, the Group achieved net
sales of USD 49.4 billion, while R&D throughout the Group amounted to
approximately USD 8.9 billion (USD 8.7 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 118,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
References
[1] HEADS-UP SURGERY FOR VITREORETINAL PROCEDURES: An Experimental and Clinical
Study.Retina. 2016 Jan;36(1):137-47.
[2] https://www.asrs.org/patients/what-is-a-retina-specialist
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Elizabeth R. Harness
Novartis Global Media Relations Novartis Alcon Communications
+41 61 324 7999 (direct) +1 817 551 8696 (direct)
+41 79 593 4202 (mobile) +1 585 435 7379 (mobile)
eric.althoff(at)novartis.com elizabeth.harness(at)alcon.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Sloan Pavsner +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2040654/761262.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 08.09.2016 - 07:15 Uhr
Sprache: Deutsch
News-ID 493428
Anzahl Zeichen: 11099
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 274 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
